STUDY OF THE BINDING OF DANOPREVIR, IVERMECTIN, LOPINAVIR, OSELTAMIVIR, REMDESIVIR AND RITONAVIR WITH THE SARS COV-2 MAIN PROTEASE USING AUTODOCK PROGRAM
In this article, using the AutoDock program, bindings of some medical preparations (danoprevir, ivermectin, lopinavir,
oseltamivir, remdesivir, and ritonavir) used in medical practice to the main protease of SARS COV-2 (Mpro, PDB ID: 6LU7)
have been studied. It has been established that the optimal range of binding energies of the abovementioned preparations with the
Mpro protein is BE=-9 ‒ -10.20 kcal/mol.
1. Chen H, Zhang Z, Wang L, Huang Z, Gong F, Li X, Chen Y, Wu JJ. Medicine (Baltimore). 2020, 99(48), e23357. doi:
10.1097/MD.0000000000023357.
2. Bryant A., Lawrie Th.A., Dowswell Th., Fordham E., Mitchell S., Hill S.R., Tham T.C. Am. J. Ther. 2021. – Vol.28(4), p
e434-e460. doi: 10.1097/MJT.0000000000001402
3. Cattaneo D., Gervasoni C., Corbellino M., Galli M., Riva A., Gervasoni C., Clementi E., Clementi E. Pharmacol. Res.
2020.-Vol.158, p.104898. doi: 10.1016/j.phrs.2020.104898.
4. Patel T.K., Patel P.B., Barvaliya M., Saurabh M.K., Bhalla H.L., Khosla P.P. J. Infect. Public. Health. 2021.-Vol.14(6), pp.
740-748. doi: 10.1016/j.jiph.2021.03.015.
5. Zendehdel A., Bidkhori M., Ansari M., Jamalimoghaddamsiyahkali S., Asoodeh A. Ann. Med. Surg. (Lond). 2022.-Vol.77,
p.103679. doi: 10.1016/j.amsu.2022.103679.
6. Taha H.R., Keewan N., Slati F., Al-Sawalha N.A. Pharmacology. 2021.-Vol.106, pp.462-468. doi: 10.1159/000518440.
7. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., Bourne P.E. Nucleic Acids Res.
2000.- Vol.28, pp.235-242. https://www.rcsb.org/
8. Stefanini I., De Renzi G., Foddai E., Cordani E., Mognetti B. Profile of Bacterial Infections in COVID-19 Patients:
Antimicrobial Resistance in the Time of SARS-CoV-2. Biology (Basel). 2021.- Vol.10(9), p.822. doi:
10.3390/biology10090822.
9. Jin, Z., Du, X., Xu, Y. et al. Structure of M pro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020.-Vol. 582,
pp.289–293. https://doi.org/10.1038/s41586-020-2223-y
10. Amin S.A., Banerjee S., Singh S., Qureshi I.A., Gayen Sh., Jha T. First structure–activity relationship analysis of
SARS‑CoV‑2 virus main protease (Mpro) inhibitors: an endeavor on COVID‑19 drug discovery. Mol Divers.-2021,
Vol. 25, 1827 doi.org/10.1007/s11030-020-10166-3
11. Ешимбетов А.Г., Жолдасов Ж., Ашуров Ж.М., Ибрагимов Б.Т. Данопревир, ивермектин, лопинавир,
осельтамивир, ремдесивир ва ритонавир препаратларининг SARS COV-2 “S-Spike” оқсилига боғланишларини
AutoDock ва AutoDock Vina дастурларида ўрганиш. НамДУ илмий ахборотномаси. 2022.- №10, 130-136 б.
12. Morris G.M., Huey R., Lindstrom W., Sanner M.F., Belew R.K., Goodsell D.S., Olson A.J. J. Comput.Chem. 2009.-
Vol.16, pp.2785-2791. https://doi.org/10.1002/jcc.21256
13. Liu X., Zhang B., Jin Z., Yang H., Rao Z. The crystal structure of COVID-19 main protease in complex with an inhibitor
N3. DOI: 10.2210/pdb6lu7/pdb
14. MGLTools v1.5.7 https://ccsb.scripps.edu/mgltools/1-5-7/
15. Krivák R., Hoksza D. J. Cheminform. 2018.-Vol.10, p.39. https://doi.org/10.1186/s13321-018-0285-8
16. BIOVIA Discovery Studio Vizualizer. https://www.3ds.com/products-services/biovia/products/molecular-modeling-
simulation/biovia-discovery-studio/
17. Туляганов Н. Фармакологическое исследование алкалоидов Peganum harmala L. хиназолиновой и хиназолоновой
структур и их производных // Фармакология природных соединений: Сб. науч. тр.-Ташкент: Фан. 1979. С.71-80.
18. Итоги исследования алкалоидоносных растений: Сб. науч. тр.- Ташкент: Фан, 1993.- C.105-132.
19. Sheng-Ge Li, Kai-Bo Wang, et al. Cytotoxic quinazoline alkaloids from the seeds of Peganum harmala. Bioorganic &
Medicinal Chemistry Letters. 2020.- Vol.28 (2), pp.103-106. doi.org/10.1016/j.bmcl.2017.12.003.
20. Natural Compounds. Alkaloids. Plant sources, Structure and Properties. Springer, New-York, 2013. DOI 10.1007/978-1-
4614-0560-3
21. https://planta-medica.uz/garmala-obyknovennaya-peganum-harmala-l/
22. https://planta-medica.uz/glycyrrhiza-glabra-l-solodka-golaya-lakrichnyj-koren/
Copyright (c) 2026 «ACTA NUUz»
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
.jpg)
1.png)
